QIVc

BIOLOGICAL5 trials

Sponsors

Novartis Vaccines, Seqirus

Conditions

HumanInfluenzaInfluenza, HumanVirus Diseases

Phase 3

Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old

CompletedNCT01992107

Novartis VaccinesInfluenza

Start: 2013-11-30End: 2014-08-31Updated: 2015-12-08

Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older

CompletedNCT01992094

Novartis VaccinesInfluenza

Start: 2013-11-30End: 2014-07-31Updated: 2015-12-10

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age

CompletedNCT03165617

SeqirusInfluenza, Human

Start: 2017-05-25End: 2019-09-30Updated: 2020-10-22

Efficacy Study With QIVc in Pediatric Subjects

CompletedNCT03932682

SeqirusInfluenza, Human

Start: 2019-05-13End: 2024-02-13Updated: 2025-03-04

Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

CompletedNCT04074928

SeqirusHuman, Influenza, Virus Diseases

Start: 2019-09-06End: 2020-09-03Updated: 2022-01-12

Related Papers

Efficacy, immunogenicity, and safety of a cell culture-derived quadrivalent influenza vaccine compared with a non-influenza vaccine in infants and children across five influenza seasons: a phase 3, multinational, observer-blind, randomised controlled trial.

2026-05-01

Efficacy of a Cell-Culture–Derived Quadrivalent Influenza Vaccine in Children

New England Journal of Medicine2021-10-1329 citations

Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial.

2015-11-1423 citations